Denmark· DK-28107225424
Tafamidis "Zentiva"
A tafamidis product containing tafamidis, registered in Denmark by Zentiva k.s.. The same ATC class is registered in 17 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Tafamidis is registered in 17 of 19 countries.
Countries holding a registration under ATC N07XX08 (tafamidis), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 9 of them publish a price we can compare per daily dose
Tafamidis · ATC N07XX08
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tafamidis costs, country by country.
Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.082 in France to $118.78 in Switzerland — a ×1457 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tafamidis · price per daily dose (20 mg)
USD · FX 28 Sept 2026
- CH Switzerland$118.78
- FR France$0.082
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Tafamidis
- Manufacturer
- Zentiva k.s.
- Country
- Denmark (DK)
- ATC code
- N07XX08
- ATC class
- Tafamidis
- Defined daily dose
- 20 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28107225424
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
18 interactions on record for tafamidis.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tafamidis · interactions on record
18 records
- 2 severe
- 16 moderate
Most severe, free to view
- OzanimodL04AA38severe
- OzanimodL04AE02severe
- EltrombopagB02BX05moderate
- LusutrombopagB02BX07moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N07XX08
Tafamidis, as other registers publish it.
- DenmarkTafamidis "Viatris"Viatris Limited
- BelgiumTafamidis AB 20 mgAurobindo
- GermanyTafamidis AlAliud Pharma Gmbh
- BelgiumTafamidis EG 61 mgEG
- SwedenTafamidis STADA Nordic 61 mg Kapsel, mjukSTADA Nordic ApS
- GermanyTafamidis ViatrisViatris Germany Gmbh
- BelgiumTafamidis Viatris 61 mgViatris GX
- SwedenTafamidis Viatris 61 mg Kapsel, mjukViatris Limited
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ebb28444-2833-45fd-a683-e0b8b7fec30a GET /v1/drugs/ebb28444-2833-45fd-a683-e0b8b7fec30a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "kapsler, bløde",
"source": "dkma",
"strength": "61 mg",
"auth_role": "CMS",
"dk_drugid": "28107225424",
"substance": "Tafamidis",
"auth_procedure": "Decentral procedure",
"in_medicinpriser": false,
"registration_date_serial": "46288"
}See everything about tafamidis.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.